CN116159104A - Application of Qishenlian eczema ointment in preparation of medicine for treating diabetic skin itch - Google Patents
Application of Qishenlian eczema ointment in preparation of medicine for treating diabetic skin itch Download PDFInfo
- Publication number
- CN116159104A CN116159104A CN202310265463.XA CN202310265463A CN116159104A CN 116159104 A CN116159104 A CN 116159104A CN 202310265463 A CN202310265463 A CN 202310265463A CN 116159104 A CN116159104 A CN 116159104A
- Authority
- CN
- China
- Prior art keywords
- parts
- qishenlian
- eczema ointment
- treatment
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003251 Pruritus Diseases 0.000 title claims abstract description 55
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 208000010668 atopic eczema Diseases 0.000 title claims abstract description 35
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 33
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 33
- 239000002674 ointment Substances 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims description 9
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 9
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 235000002566 Capsicum Nutrition 0.000 claims abstract description 5
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 5
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 5
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 5
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 5
- 239000006002 Pepper Substances 0.000 claims abstract description 5
- 235000016761 Piper aduncum Nutrition 0.000 claims abstract description 5
- 235000017804 Piper guineense Nutrition 0.000 claims abstract description 5
- 235000008184 Piper nigrum Nutrition 0.000 claims abstract description 5
- 229940116229 borneol Drugs 0.000 claims abstract description 5
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940105847 calamine Drugs 0.000 claims abstract description 5
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 5
- 229910052864 hemimorphite Inorganic materials 0.000 claims abstract description 5
- 235000011477 liquorice Nutrition 0.000 claims abstract description 5
- 239000011787 zinc oxide Substances 0.000 claims abstract description 5
- 235000014692 zinc oxide Nutrition 0.000 claims abstract description 5
- CPYIZQLXMGRKSW-UHFFFAOYSA-N zinc;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+3].[Fe+3].[Zn+2] CPYIZQLXMGRKSW-UHFFFAOYSA-N 0.000 claims abstract description 5
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 244000203593 Piper nigrum Species 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 53
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 7
- 241000180649 Panax notoginseng Species 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- 230000001804 emulsifying effect Effects 0.000 claims description 3
- 229940057995 liquid paraffin Drugs 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- 238000011160 research Methods 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 208000024891 symptom Diseases 0.000 description 21
- 230000000694 effects Effects 0.000 description 13
- 230000007803 itching Effects 0.000 description 11
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 206010039509 Scab Diseases 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 229960003596 cyproheptadine hydrochloride Drugs 0.000 description 4
- ZPMVNZLARAEGHB-UHFFFAOYSA-N cyproheptadine hydrochloride (anhydrous) Chemical compound Cl.C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 ZPMVNZLARAEGHB-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 241000722363 Piper Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010024438 Lichenification Diseases 0.000 description 2
- 208000028389 Nerve injury Diseases 0.000 description 2
- 206010040867 Skin hypertrophy Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000008764 nerve damage Effects 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000218202 Coptis Species 0.000 description 1
- 235000002991 Coptis groenlandica Nutrition 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 102000001490 Opioid Peptides Human genes 0.000 description 1
- 108010093625 Opioid Peptides Proteins 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000003399 opiate peptide Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000013139 quantization Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/758—Zanthoxylum, e.g. pricklyash
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an application of Qishenlian eczema ointment in preparing a medicine for treating diabetic skin itch, belonging to the technical field of biological medicine. The Qishenlian eczema ointment comprises the following raw materials in parts by weight: 45 parts of coptis chinensis, 40 parts of radix sophorae flavescentis, 35 parts of rhizoma atractylodis, 40 parts of rhizoma paridis, 15 parts of pseudo-ginseng, 30 parts of cortex dictamni, 30 parts of calamine, 20 parts of pepper, 15 parts of borneol and 30 parts of liquorice. Research results show that the Qishenlian eczema ointment can effectively treat the skin pruritus of diabetes, has low recurrence rate, is safe to use and is easy to popularize and apply.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to application of Qihan Lian eczema ointment in preparation of a medicine for treating diabetic skin itch.
Background
The diabetic skin pruritus is skin lesions caused by microvascular disorder, nerve damage and the like caused by diabetes, namely, the diabetic patients have no skin primary damage, but skin pruritus is the skin disease which is mainly clinically represented, and the severe patients can have scratch marks, scabs, skin hypertrophy and lichenification. Itching is mainly caused by the change of blood plasma and interstitial fluid osmotic pressure caused by the rise or decrease of blood sugar, and is generated by stimulating nerve ending excitation, and is one of common complications of diabetics, the incidence rate of the itching can reach 7% -43% in the diabetics, and the itching is 2.7 times of that of non-diabetics.
At present, western medicine has no specific therapy for diabetes complicated with skin itch, and generally adopts an antiallergic therapy on the basis of diabetes basic treatment, but has certain side effects and is easy to relapse. Modern research has suggested that endogenous opioid peptides play an important role in nerve and mental regulation as well as an antipruritic effect on the nerves, and that such antipruritic effect is not caused by histamine release or prostaglandin formation. Therefore, the traditional Chinese medicine preparation with the efficacy of treating both principal and secondary aspect of disease has important clinical significance in discussing.
The patent CN1125117A 'eczema ointment' related to the invention is an invention patent declared by the precursor Kunming city torch technology development industry company Wang Dengke et al 1994.12.22 of the applicant of the invention. The seven-ginseng-to-link eczema ointment produced by the applicant is a product preferred by the patent, the approval document is national medicine standard B20020221, the execution standard is WS-5400 (B-0400) -2014Z, and the functions and indications are as follows: clearing heat and drying dampness, activating blood and detumescence, dispelling wind and relieving itching. Can be used for treating eczema due to wind dampness, heat, toxic materials, and blood stasis. Is widely used on the market, and achieves better treatment effect. However, the action mechanism of the traditional Chinese medicine is mainly to treat eczema exudation caused by wind dampness, heat and toxin stagnation, and no evidence exists to show that the traditional Chinese medicine has positive effects on skin lesions caused by microvascular disorder, nerve damage and the like caused by diabetes. Therefore, how to overcome the defects of the prior art is a problem which needs to be solved in the technical field of the biological medicine at present.
Disclosure of Invention
The invention aims to solve the defects of the prior art and provides application of Qishenlian eczema ointment in preparing a medicament for treating diabetic skin disease and pruritus.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
application of QISHENLIAN eczema ointment in preparing medicine for treating diabetic skin pruritus is provided.
Further, preferably, the seven-ginseng and even eczema ointment comprises the following raw materials in parts by weight:
45 parts of coptis chinensis, 40 parts of radix sophorae flavescentis, 35 parts of rhizoma atractylodis, 40 parts of rhizoma paridis, 15 parts of pseudo-ginseng, 30 parts of cortex dictamni, 30 parts of calamine, 20 parts of pepper, 15 parts of borneol and 30 parts of liquorice.
Further, preferably, the preparation method of the Qishenlian eczema ointment comprises the following steps:
pulverizing Coptidis rhizoma, radix Sophorae Flavescentis, rhizoma Atractylodis, rhizoma paridis, cortex Dictamni Radicis, fructus Zanthoxyli and Glycyrrhrizae radix into coarse powder, soaking in 5 times of water for 1 hr, boiling for 1 hr, filtering, adding 3 times of water, decocting for 1 hr, filtering, mixing three extractive solutions, and concentrating to obtain concentrated solution;
pulverizing Notoginseng radix, galamina, and Borneolum respectively, sieving with 100 mesh sieve, and collecting undersize;
heating the concentrated solution to 90 ℃ in a water bath, adding 1 part by weight of potassium hydroxide and 3.6 parts by weight of triethanolamine, and adding ethanol to dissolve the mixture to obtain a water phase;
heating 45 parts of stearic acid, 24 parts of glycerol, 1.5 parts of stearyl alcohol and 21 parts of liquid paraffin in a water bath to 90 ℃ to melt the mixture, and taking the mixture as an oil phase; heating in water bath, adding water phase, stirring, emulsifying, stirring, adding Galamina, notoginseng radix and Borneolum Syntheticum powder at a time, and mixing to uniformity to obtain 1000 parts.
Further, it is preferable that the weight ratio of the volume of the concentrated solution to the cortex dictamni is 6mL:1g.
Further, it is preferable that the volume ratio of the weight of potassium hydroxide to ethanol is 1g:15mL.
The invention is not limited to the particle size of the coarse powder, and may be limited according to conventional techniques in the art.
The stirring speed is not limited, and the stirring method is carried out according to a conventional method.
The skin pruritus caused by diabetes is a chronic skin complication of diabetes, and the pathogenesis of the skin pruritus is not completely clear. The inventor finds that diabetes mellitus is the primary disease of pruritus, the pathogenesis is multiple, deficiency and excess are mixed, the involvement is wide, if the treatment is improper, the treatment lasts for a long time, the qi and the yin are insufficient, dryness heat is generated internally, nutrient and blood are deficient, blood vessels are not full, blood circulation is unsmooth to cause blood stasis, blood deficiency, blood heat and blood stasis can generate wind, and moreover, spleen deficiency is easy to generate internal dampness or striae and interstitial is unstable, exogenous wind-damp heat evil is accumulated on skin, and skin is malnourished, skin pruritus is caused.
The QISHENLIAN eczema ointment has effects of clearing heat, eliminating dampness, promoting blood circulation, relieving swelling, dispelling pathogenic wind, and relieving itching, and can be applied to the pathogenesis of the disease. The plaster comprises rhizoma Coptidis, radix Sophorae Flavescentis, rhizoma Atractylodis, rhizoma paridis, radix Notoginseng, cortex Dictamni, galamina, fructus Zanthoxyli, borneolum Syntheticum, and radix Glycyrrhizae. The traditional Chinese medicine composition is mainly used for treating eczema, skin pruritus and the like caused by wind dampness, heat, toxin and blood stasis. Wherein, pseudo-ginseng has the effects of activating blood circulation to dissipate blood stasis and relieving swelling and pain as a monarch; kuh-seng and coptis root are ministerial drugs for clearing heat and drying dampness, purging fire and detoxicating; rhizoma atractylodis and cortex dictamni are added for dispelling wind and eliminating dampness, rhizoma paridis for detoxication and detumescence, calamine and borneol for drawing out toxin and relieving itching, and pepper for warming and relieving itching; the liquorice regulates the medicines. The medicines are compatible, and have the effects of dispelling wind and eliminating dampness, and detoxifying and relieving itching.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention provides application of Qishenlian eczema ointment in preparing a medicament for treating diabetic skin itch, and research results show that: the pruritus degree, the pruritus area, the pruritus frequency, the duration and the scratch mark of the cyproheptadine hydrochloride emulsifiable paste which are the seven-ginseng-to-eczema ointment and the antihistamine medicines are obviously reduced (P is less than 0.05), the pruritus degree, the pruritus area, the duration and the scratch mark of the cyproheptadine hydrochloride emulsifiable paste of the seven-ginseng-to-eczema ointment are more obviously reduced (P is less than 0.05), and the recurrence rate of the treatment group is lower than that of the control group; the Qishenlian eczema ointment can effectively treat the skin pruritus of diabetes, has low recurrence rate, is safe to use and is easy to popularize and apply.
2. The Qishenlian eczema ointment has the functions of clearing heat and drying dampness, activating blood and relieving swelling, dispelling wind and relieving itching, and is capable of treating both symptoms and root causes;
3. compared with antihistamines, the preparation has more remarkable advantages and less side effects;
4. the invention can also have beneficial effects on the main symptoms of diabetics, and the details are shown in table 3.
Detailed Description
The present invention will be described in further detail with reference to examples.
It will be appreciated by those skilled in the art that the following examples are illustrative of the present invention and should not be construed as limiting the scope of the invention. The specific techniques or conditions are not identified in the examples and are performed according to techniques or conditions described in the literature in this field or according to the product specifications. The materials or equipment used are conventional products available from commercial sources, not identified to the manufacturer.
The Qishenlian eczema ointment comprises the following raw materials in parts by weight:
45 parts of coptis chinensis, 40 parts of radix sophorae flavescentis, 35 parts of rhizoma atractylodis, 40 parts of rhizoma paridis, 15 parts of pseudo-ginseng, 30 parts of cortex dictamni, 30 parts of calamine, 20 parts of pepper, 15 parts of borneol and 30 parts of liquorice.
The preparation method of the Qishenlian eczema ointment comprises the following steps:
pulverizing Coptidis rhizoma, radix Sophorae Flavescentis, rhizoma Atractylodis, rhizoma paridis, cortex Dictamni Radicis, fructus Zanthoxyli and Glycyrrhrizae radix into coarse powder, soaking in 5 times of water (5 times of the total mass of Coptidis rhizoma, radix Sophorae Flavescentis, rhizoma Atractylodis, rhizoma paridis, cortex Dictamni Radicis, fructus Zanthoxyli and Glycyrrhrizae radix) for 1 hr, boiling for 1 hr, filtering, decocting the residue with 3 times of water (3 times of the residue mass) for 2 times, 1 hr each time, filtering, mixing three extractive solutions, and concentrating; the weight ratio of the volume of the concentrated solution to the cortex dictamni is 6mL:1g;
pulverizing Notoginseng radix, galamina, and Borneolum respectively, sieving with 100 mesh sieve;
heating the concentrated solution to 90 ℃ in a water bath, adding 1 part by weight of potassium hydroxide and 3.6 parts by weight of triethanolamine, and adding ethanol to dissolve the concentrated solution to obtain a water phase; the volume ratio of the weight of potassium hydroxide to ethanol is 1g:15mL;
adding 45 parts of stearic acid, 24 parts of glycerol, 1.5 parts of stearyl alcohol and 21 parts of liquid paraffin into a water bath kettle in a container to dissolve at 90 ℃ to obtain an oil phase; heating in water bath, introducing water phase, stirring, emulsifying, stirring, sequentially adding Galamina, notoginseng radix and Borneolum Syntheticum powder, and mixing to uniformity to obtain 1000 parts.
Clinical experiments prove that the prepared Qishenlian eczema ointment has the effect of effectively treating the skin pruritus caused by diabetes.
1 clinical data
1.1 diagnostic criteria
(1) Western diagnostic criteria
Referring to the diagnosis standard of the diabetes mellitus complicated skin pruritus in the traditional Chinese medicine control guideline of diabetes mellitus complicated skin diseases, which is formulated by the Chinese medical society: 1) A history of diabetes; 2) No primary skin damage; 3) Paroxysmal systemic or local skin itching may be accompanied by scratches, scabs, skin hypertrophy, lichenification, pigmentation, etc.
(2) Dialectical standard of Chinese medicine
Reference to the "guidelines for clinical research of New Chinese medicine" (first edit) the guidelines for clinical research of New Chinese medicine for treating wind-itching "refers to the criteria for syndrome differentiation.
Main symptoms are as follows: itching of the skin, desquamation of the rash, scratch of the scab;
secondary symptoms: dry skin, hypertrophic and mossy, bitter taste and thirst, and dysphoria;
pulse condition of tongue: a red tongue with yellow coating and a thready pulse.
(3) Grading and quantifying standard for symptom signs
According to the contents of Chinese clinical dermatology and related documents, the symptoms (pruritus degree, area, frequency and duration) and signs (dryness, scales, scratches, scabs, pimples and moss) of patients are quantified, and are classified into 4 grades according to the non-, mild-, moderate-and severe grades, namely 0, 2, 4 and 6 grades respectively. See table 1.
Table 1 symptom and sign grading quantization table
Note that: the pruritus area is estimated according to the adult body surface area Chinese ninth method; the tongue pulse is recorded only without scores.
(4) Grading standard of disease degree
Mild, the integral of the symptoms of the traditional Chinese medicine is less than or equal to 16 minutes; moderate, chinese medicine symptom integral 17-32 points; severe symptom score of Chinese medicine is greater than or equal to 33 minutes.
1.2 inclusion criteria
Meets the western medicine diagnosis and the traditional Chinese medicine differentiation standard; age 18-75 years old; other clinical trials of the drug have not been carried out in nearly 2 weeks, and traditional Chinese medicines (Chinese patent medicines and decoction) and western medicines (antihistamine, glucocorticoid and the like) related to the treatment of the disease have not been used in 1 week; the patient informed consent.
1.3 exclusion criteria
Mental patients; pregnant or lactating women; allergic constitution or allergic to test drugs; patients are reluctant to cooperate with the therapy.
1.4 general data
72 cases of diabetic skin pruritus patients in the traditional Chinese medicine hospitals of the Yunnan province, the Yunnan pleasant rehabilitation hospitals and the home-care nursing homes of the Yunnan aged in 2021 month to 2022 month 3 are selected, and 36 cases of the treatment group and the control group are respectively divided by adopting a random digital table method. 24 cases were assigned to each of 3 medical institutions, and 12 cases were assigned to each of the treatment group and the control group. 17 men and 19 women in the treatment group; age 41-75 years, average (59.62+ -12.27) years; the disease course is 6-23 years, and the average (14.32+/-4.48) years. 20 men and 16 women in the control group; age 39-73 years, average (58.12 ±13.67) years; the disease course is 5-22 years, and the average (15.67+/-5.16) years. The difference between the general data of two groups of patients is not statistically significant (P > 0.05), and the two groups of patients are comparable.
2 method
2.1 methods of treatment
Basic treatment: both groups carry out the knowledge and education of diabetes, improve the treatment compliance and ensure the good implementation and execution of treatment measures; keep diet control and reasonable exercise; the hypoglycemic drugs are reasonably selected, so that the blood sugar is kept stable, the fasting blood sugar is less than or equal to 7.0mmol/L, the postprandial blood sugar is less than or equal to 10.0mmol/L for 2 hours, and the glycosylated hemoglobin is less than 7 percent.
Treatment group: the ointment (10 g each of which is produced by Yunnan blue-green kang pharmaceutical industry Co., ltd., national drug standard B20020421) is added for external use at the same time in basic treatment, and a proper amount of the ointment is applied to an affected part for 3 times a day.
Control group: the basic treatment is added with cyproheptadine hydrochloride emulsifiable paste (10 g each, manufactured by Hunan Wuzhou Tong pharmaceutical industry Co., ltd.) for external use, and the Chinese medicine standard H20066349 is applied to the affected part with a proper amount for 3 times per day.
Note that: the invention is not limited in use amount, and can be carried out according to conventional technical means in the field.
Both treatment courses were 14 days. Neither group was combined with other treatments during the treatment period, and was prohibited to eat spicy raw and cold foods.
2.2 observations index and method
2.2.1 blood glucose levels two groups of patients were tested for fasting blood glucose and postprandial 2h blood glucose before and after treatment.
2.2.2 symptom sign scoring
The standard of quantitative grading of symptom signs is shown in Table 1, and each record is 1 time before and after treatment.
2.2.3 adverse reactions of two groups of patients were observed during the treatment, and blood, urine, stool, and liver and kidney functions were detected before and after the treatment.
Recurrence was followed 2 weeks after treatment.
2.3 therapeutic efficacy criterion
The total integral of symptoms and signs before and after treatment was calculated with reference to the therapeutic effect determination criteria for diabetic cutaneous pruritus in the "chinese clinical dermatology" and related literature, and the therapeutic effect index= (pre-treatment integral-post-treatment integral)/pre-treatment integral×100% was calculated. And (3) healing: the clinical symptoms and physical signs disappear, and the curative effect index is more than or equal to 95%; the effect is shown: the clinical symptoms and the physical signs are obviously improved, and the curative effect index is [70%, 95%); the method is effective: the clinical symptoms and physical signs are improved, and the curative effect index is 30 percent and 70 percent; invalidation: the clinical symptoms and physical signs are not improved or aggravated, and the curative effect index is less than 30 percent.
2.4 statistical methods
Statistical analysis was performed using SPSS24.0 software. The counting data is expressed by the number of examples and percentage, and the metering data is expressed by mean ± standard deviation (x ± s); the counting data is compared by X2 test, and the metering data is compared by t test. P < 0.05 is statistically significant for the differences.
3 results
3.1 comparison of clinical efficacy of two groups of patients
Of 36 patients in the treatment group, 4 (11.1%), 12 (33.3%), 16 (44.4%), 4 (11.1%), and 32 (88.9%) were cured. Out of 36 patients in the control group, 2 cases (5.6%), 6 cases (16.7%), 18 cases (50.0%), 10 cases (27.8%) and 26 cases (72.2%) were cured. The difference of the total effective rate of the two groups of clinical curative effects is statistically significant (P is less than 0.05), and the treatment group is superior to the control group. See table 2.
Table 2 comparison of therapeutic effects in the treated group and the control group
3.2 comparison of blood glucose before and after treatment of two groups of patients
The fasting blood glucose and postprandial blood glucose of the two groups of patients are reduced compared with those before treatment, but the difference has no statistical significance (P is more than 0.05). See table 3.
TABLE 3 comparison of blood glucose before and after treatment (mmol/L, x.+ -. S) for two groups of patients
3.3 comparison of sign scores of symptoms before and after treatment for two groups of patients
The symptom integral of the two groups of patients after treatment is obviously reduced (P is less than 0.05) compared with that of the two groups of patients before treatment, and the pruritus degree, pruritus area, duration and scratch and scab integral of the treatment group are obviously reduced (P is less than 0.05) compared with that of the control group. See table 4.
Table 4 comparison of sign scores of symptoms before and after treatment (score, x.+ -. S) for two groups of patients
Compared with the prior treatment of the group, the ∈P is less than 0.05; delta P < 0.05 compared to control post-treatment.
3.4 comparison of recurrence after treatment for two groups of patients
Following 1 week after the end of treatment, 12 cases (33.31%) of treatment recurred, 21 cases (58.3%) of control recurred, and the comparison difference of the two recurred rates was statistically significant (P < 0.05), and the recurrence rate of the treatment was lower than that of the control. See table 5.
Table 5 comparison of recurrence of the treated group with the control group
| Group of | Number of examples | Recurrence (percent) |
| Treatment group | 36 | 12(33.31％) |
| Control group | 36 | 21(58.3％) |
3.5 adverse reactions
No adverse reactions occurred in the treatment and control groups during the treatment period. The blood, urine and stool are normal before and after the treatment, and the liver and kidney functions and the electrocardiogram are not abnormal.
Results the pruritus degree, pruritus area, pruritus frequency, duration and scratch and scab integral of both groups after treatment are obviously reduced (P < 0.05), and the pruritus degree, pruritus area, duration and scratch and scab integral of the treatment groups are obviously reduced (P < 0.05); the total effective rate of the treatment group is 32 cases (88.9%), the total effective rate of the control group is 26 cases (72.2%), and the comparison difference of the two groups of total effective rates has statistical significance (P is less than 0.05); the treatment group recurred 12 cases (33.31%) after 2 weeks from the end of treatment, the control group recurred 21 cases (58.3%), and the comparison difference of the two recurrence rates has statistical significance (P < 0.05), and the recurrence rate of the treatment group is lower than that of the control group.
Conclusion 4
4.1 the external use of the Qishenlian eczema ointment can effectively improve the symptoms of patients with the skin pruritus caused by diabetes.
4.2 the external use of the seven-ginseng and even eczema ointment has more obvious symptoms for improving patients with the skin itch of diabetes compared with the external use of the cyproheptadine hydrochloride emulsifiable paste.
4.3 the external use of the Qishenlian eczema ointment has lower recurrence rate for treating the skin pruritus of diabetes.
4.4 the external use of the Qishenlian eczema ointment has no obvious adverse reaction and safe clinical application.
The foregoing has shown and described the basic principles, principal features and advantages of the invention. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, and that the above embodiments and descriptions are merely illustrative of the principles of the present invention, and various changes and modifications may be made without departing from the spirit and scope of the invention, which is defined in the appended claims. The scope of the invention is defined by the appended claims and equivalents thereof.
Claims (5)
1. Application of QISHENLIAN eczema ointment in preparing medicine for treating diabetic skin pruritus is provided.
2. The application of the Qishenlian eczema ointment according to claim 1 in preparing a medicine for treating diabetic skin itch, which is characterized in that the Qishenlian eczema ointment comprises the following raw materials in parts by weight:
45 parts of coptis chinensis, 40 parts of radix sophorae flavescentis, 35 parts of rhizoma atractylodis, 40 parts of rhizoma paridis, 15 parts of pseudo-ginseng, 30 parts of cortex dictamni, 30 parts of calamine, 20 parts of pepper, 15 parts of borneol and 30 parts of liquorice.
3. The application of the Qishenlian eczema ointment according to claim 2 in preparing a medicament for treating diabetic skin itch, which is characterized in that the preparation method of the Qishenlian eczema ointment comprises the following steps:
pulverizing Coptidis rhizoma, radix Sophorae Flavescentis, rhizoma Atractylodis, rhizoma paridis, cortex Dictamni Radicis, fructus Zanthoxyli and Glycyrrhrizae radix into coarse powder, soaking in 5 times of water for 1 hr, boiling for 1 hr, filtering, adding 3 times of water, decocting for 1 hr, filtering, mixing three extractive solutions, and concentrating to obtain concentrated solution; pulverizing Notoginseng radix, galamina, and Borneolum respectively, sieving with 100 mesh sieve, and collecting undersize;
heating the concentrated solution to 90 ℃ in a water bath, adding 1 part by weight of potassium hydroxide and 3.6 parts by weight of triethanolamine, and adding ethanol to dissolve the mixture to obtain a water phase;
heating 45 parts of stearic acid, 24 parts of glycerol, 1.5 parts of stearyl alcohol and 21 parts of liquid paraffin in a water bath to 90 ℃ to melt the mixture, and taking the mixture as an oil phase; heating in water bath, adding water phase, stirring, emulsifying, stirring, adding Galamina, notoginseng radix and Borneolum Syntheticum powder at a time, and mixing to uniformity to obtain 1000 parts.
4. The use of the paste for treating diabetic skin itch according to claim 3, wherein the weight ratio of the volume of the concentrated solution to the cortex dictamni is 6mL:1g.
5. Use of the paste according to claim 3 for the preparation of a medicament for the treatment of diabetic cutaneous pruritus, characterized in that the ratio by volume of potassium hydroxide to ethanol is 1g:15mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310265463.XA CN116159104A (en) | 2023-03-20 | 2023-03-20 | Application of Qishenlian eczema ointment in preparation of medicine for treating diabetic skin itch |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310265463.XA CN116159104A (en) | 2023-03-20 | 2023-03-20 | Application of Qishenlian eczema ointment in preparation of medicine for treating diabetic skin itch |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116159104A true CN116159104A (en) | 2023-05-26 |
Family
ID=86414710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310265463.XA Pending CN116159104A (en) | 2023-03-20 | 2023-03-20 | Application of Qishenlian eczema ointment in preparation of medicine for treating diabetic skin itch |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116159104A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300574A (en) * | 2022-06-24 | 2022-11-08 | 朱明浩 | Application of eczema ointment containing seven kinds of ginseng and coptis in preparation of medicine for treating neurodermatitis |
-
2023
- 2023-03-20 CN CN202310265463.XA patent/CN116159104A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115300574A (en) * | 2022-06-24 | 2022-11-08 | 朱明浩 | Application of eczema ointment containing seven kinds of ginseng and coptis in preparation of medicine for treating neurodermatitis |
Non-Patent Citations (1)
| Title |
|---|
| 沈毅: "七参连软膏治疗阴囊瘙痒症疗效观察", 《数理医药学杂志》, vol. 26, no. 4, pages 465 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100998650A (en) | Use of cinnamonum cassia for treating diabetes, its products and preparing method | |
| WO2022021639A1 (en) | Traditional chinese medicine composition for invigorating spleen and activating yang, and use thereof | |
| CN101972334B (en) | Traditional Chinese medicine preparation for preventing and treating infantile eczema and preparation method thereof | |
| CN116159104A (en) | Application of Qishenlian eczema ointment in preparation of medicine for treating diabetic skin itch | |
| CN114404538B (en) | Traditional Chinese medicine composition for treating gouty arthritis and application thereof | |
| CN112138084B (en) | Traditional Chinese medicine composition for treating bronchiectasis qi-yin deficiency and phlegm-heat obstructing lung and application thereof | |
| CN111743942A (en) | Traditional Chinese medicine composition for treating acute exacerbation of chronic obstructive pulmonary disease and preparation method thereof | |
| CN110624067B (en) | Traditional Chinese medicine composition with weight-losing effect and preparation method of ointment thereof | |
| WO2017152834A1 (en) | Phylloporia fontanesiae and use thereof in preparing drug | |
| CN111588757A (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease in stable phase and preparation method thereof | |
| CN1301725C (en) | Wasting-thirst capsule of root powder for treating diabetes | |
| CN112138105B (en) | Traditional Chinese medicine composition for treating bronchiectasis lung-spleen qi deficiency and phlegm-damp lung blocking syndrome and application thereof | |
| CN116920047B (en) | Novel traditional Chinese medicine compound composition for treating myocardial injury related to coronavirus infection and preparation method thereof | |
| CN104740345B (en) | Treat Chinese medicine composition of diabetes and preparation method thereof | |
| CN107551153B (en) | Medicine for treating diabetic nephropathy and preparation method thereof | |
| CN112741872B (en) | Traditional Chinese medicine composition and preparation method and application thereof | |
| CN110433204B (en) | Chinese medicine compound preparation and its preparing method and use | |
| CN114617924B (en) | Composition for treating type 2 diabetes | |
| CN117883543A (en) | Traditional Chinese medicine composition, preparation and application thereof | |
| CN117018105A (en) | Traditional Chinese medicine composition for treating impaired glucose tolerance and preparation method thereof | |
| CN106620318B (en) | Traditional Chinese medicine composition for treating chronic nephritis | |
| CN1562222A (en) | Medicination for curing kidney disease and preparation method | |
| CN114504626A (en) | She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome | |
| CN115120697A (en) | Tibetan medicine composition and preparation method and application thereof | |
| CN116327870A (en) | Composition for relieving insomnia symptom, application, medicine and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |